Hemagenleukleucel

N/A

Report date: 2024/11/27 20:00:40

Base Information

Drug NameHemagenleukleucel

Drug Alias NameHem101Hem-101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian Federation

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesNational Research Center For Hematology, Moscow, Russia

China Registration ClassN/A

Develop Information

Active CompaniesNational Research Center For Hematology, Moscow, Russia

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A